Abstract
Aldose reductase (AR) was cloned from the fungal pathogen, Magnaporthe grisea, expressed in Escherichia coli and purified to homogeneity. An experimental fungicide inhibits the M. grisea AR uncompetitively with respect to its aldehyde substrate with a Ki of 130 nM, the potency suggesting that AR is a biochemical target of the fungicide. The M. grisea AR has a high kcat and large differences in substrate specificities.
Keywords: fungal ALDOSE REDUCTASE, Magnaporthe grisea
Protein & Peptide Letters
Title: Inhibition of Fungal Aldose Reductase
Volume: 8 Issue: 5
Author(s): Ya-Jun Zheng, Yong Tao, Wei Zhang and Douglas B. Jordan
Affiliation:
Keywords: fungal ALDOSE REDUCTASE, Magnaporthe grisea
Abstract: Aldose reductase (AR) was cloned from the fungal pathogen, Magnaporthe grisea, expressed in Escherichia coli and purified to homogeneity. An experimental fungicide inhibits the M. grisea AR uncompetitively with respect to its aldehyde substrate with a Ki of 130 nM, the potency suggesting that AR is a biochemical target of the fungicide. The M. grisea AR has a high kcat and large differences in substrate specificities.
Export Options
About this article
Cite this article as:
Zheng Ya-Jun, Tao Yong, Zhang Wei and Jordan B. Douglas, Inhibition of Fungal Aldose Reductase, Protein & Peptide Letters 2001; 8 (5) . https://dx.doi.org/10.2174/0929866013409210
DOI https://dx.doi.org/10.2174/0929866013409210 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Anti-diabetic Effect of Ginsenoside Rb3 in Alloxan-induced Diabetic Mice
Medicinal Chemistry Kainic Acid-Induced Neurotoxicity: Targeting Glial Responses and Glia-Derived Cytokines
Current Neuropharmacology The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Suppression of Inflammatory and Allergic Responses by Pharmacologically Potent Fungus Ganoderma lucidum
Recent Patents on Inflammation & Allergy Drug Discovery Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Current Drug Delivery An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Signaling Pathways Involved in Physiopathology of Pancreatic β -Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Correlation Between ROS Production and InsP3 Released by Granulocytes from Type 1 Diabetic Patients in a cAMP-Dependent Manner
Current Aging Science Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Combination of Naringenin and Lisinopril Ameliorates Nephropathy in Type-1 Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Design, Synthesis and Biological Activity of New Polyenolic Inhibitors of Matrix Metalloproteinases: A Focus on Chemically-Modified Curcumins
Current Medicinal Chemistry Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews